Inotiv, inc. announces expansion of pharmacology and pathology offerings with agreement to purchase bolder biopath, inc.

West lafayette, ind., april 16, 2021 (globe newswire) -- inotiv, inc. (nasdaq:notv) (the “company”, “we”, “our” or “inotiv”), a leading provider of non-clinical and analytical contract research services, today announced that the company has entered into an agreement and plan of merger with bolder biopath, inc. (“bolder biopath”), a contract pharmacology and pathology company specializing in in vivo models of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, diseases of the central nervous system and other autoimmune, inflammation, and pain models.
NOTV Ratings Summary
NOTV Quant Ranking